Rothschild Redb Upgrades Novo Nordisk A/S (NYSE:NVO) to Strong-Buy

Novo Nordisk A/S (NYSE:NVO) was upgraded by Rothschild Redb from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other equities analysts have also commented on the stock. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $81.00.

Novo Nordisk A/S Stock Up 1.7%

NVO stock opened at $58.20 on Tuesday. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $135.20. The firm has a market cap of $259.86 billion, a PE ratio of 15.99, a PEG ratio of 2.17 and a beta of 0.66. The firm’s 50 day moving average price is $57.21 and its 200-day moving average price is $65.81. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the company. NWF Advisory Services Inc. acquired a new position in Novo Nordisk A/S during the second quarter worth $540,000. Reynders McVeigh Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth about $25,116,000. American Trust grew its stake in Novo Nordisk A/S by 43.9% in the 2nd quarter. American Trust now owns 7,721 shares of the company’s stock valued at $533,000 after acquiring an additional 2,356 shares during the last quarter. Centaurus Financial Inc. raised its position in Novo Nordisk A/S by 9.4% during the second quarter. Centaurus Financial Inc. now owns 11,099 shares of the company’s stock worth $766,000 after acquiring an additional 950 shares during the last quarter. Finally, Saratoga Research & Investment Management raised its position in shares of Novo Nordisk A/S by 4.0% during the 2nd quarter. Saratoga Research & Investment Management now owns 1,512,677 shares of the company’s stock worth $104,405,000 after purchasing an additional 58,517 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.